HER2+ advanced breast cancer: primary results from the phase 3 MARIANNE study

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • In human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, trastuzumab emtansine (T-DM1; Kadcycla) with or without pertuzumab (Perjeta) was noninferior in efficacy, but more tolerable than taxane plus trastuzumab (Herceptin).
Why this matters
  • T-DM1 with or without pertuzumab is another treatment option for HER2-positive breast cancer.
Study design
  • 1095 women in 38 countries were randomly assigned to T-DM1 plus placebo, T-DM1 plus pertuzumab, or taxane plus trastuzumab (control group).
  • PFS was the primary outcome measure.
  • Funding: F. Hoffmann-La Roche.
Key results
  • Median PFS was noninferior in T-DM1 (14.1 mo) and T-DM1 plus pertuzumab (15.2 ...